Biote Corp. Reports Steep Q1 Profit Decline Amid Product Recall, Reaffirms Full-Year Guidance
BTMD sits 69% above its 52-week low of $1.27.
Summary
Biote Corp. reported a substantial decline in Q1 net income and Adjusted EBITDA, with revenue falling due to a voluntary product recall, though full-year guidance was reaffirmed with a lowered outlook for H1 procedure revenue.
Key Events · Earnings and Guidance · BTMD
-
Significant Profit Decline
Net income plummeted to $2.7 million ($0.06 diluted EPS) in Q1 2026, a sharp decrease from $15.8 million ($0.37 diluted EPS) in Q1 2025.
-
Revenue Contraction
Total revenue decreased 8.3% to $44.9 million, with procedure revenue declining 13.2% to $31.3 million, primarily due to a voluntary product recall.
-
Adjusted EBITDA Plunge
Adjusted EBITDA fell 36.6% to $8.7 million, with the Adjusted EBITDA margin contracting to 19.4% from 28.1% in the prior-year quarter.
-
Product Recall Impact
The voluntary recall of certain hormone pellet products led to higher sourcing costs for replacement products and reduced manufacturing efficiencies, significantly impacting gross profit margins.
Analysis · BTMD · Life Sciences
Biote Corp.'s first-quarter results show a significant decline in profitability, primarily driven by an 8.3% drop in total revenue and a 13.2% decrease in procedure revenue. The voluntary recall of certain hormone pellet products and associated higher costs severely impacted gross profit margins and net income. While management reaffirmed full-year revenue and Adjusted EBITDA guidance, the expectation for first-half procedure revenue growth has been moderately lowered, indicating continued near-term headwinds. Investors should monitor the company's progress in resolving supply constraints and achieving its stated goal of sales force expansion, as a return to procedure revenue growth in the second half of 2026 is critical for recovery. This follows the previous 8-K from April 3, 2026, which projected an EBITDA decline, now confirmed with specific Q1 figures.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.5% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BTMD was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.5M. The 52-week trading range was $1.27 to $4.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.